By writer to www.biospace.com
SOUTH SAN FRANCISCO, Calif., July 15, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a number one precision drugs firm targeted on the invention, improvement, and commercialization of clinically differentiated, high-value healthcare options for transplant sufferers and caregivers, declares right this moment that Peter Maag, Chairman and CEO of CareDx, will current at a panel hosted by the American Affiliation of Kidney Sufferers (AAKP) and the George Washington College Faculty of Medication and Well being Sciences on “Rising Innovation in Kidney Illness with International Implications: Synthetic Intelligence in Transplant Care.” The summit is scheduled to be held from July 16 to July 17, 2020.
Augmented intelligence reveals robust potential for enhancing medical decision-making and enhancing affected person care in transplantation. A transplant affected person will typically search care at a transplant heart after spending years on dialysis and whereas receiving ongoing administration with a normal nephrologist. Consequently, these sufferers can face siloed or lacking data that may result in worse particular person care.
CareDx has a collection of digital transplant instruments to assist clear up the issue in managing disperse data, with options for transplant facilities and sufferers immediately. In his presentation, Mr. Maag will probably be highlighting AiTraC for clinician choice help and AlloCare for affected person well being engagement.
“The AAKP/GW International Summit on Kidney Illness is now the most important patient-led kidney summit on this planet and has expanded to incorporate AI know-how specialists and a various vary of well being professionals. Our contributors embody sufferers and healthcare system influencers throughout South America, India, Europe, and Asia, with an intense curiosity in illness prevention, organ transplantation, and illness diagnostics,” acknowledged Richard Knight, president of AAKP and transplant recipient. “CareDx is a pacesetter in healthcare improvements for the transplant sufferers and the broader transplant neighborhood, and AAKP is happy to have Peter focus on how data-driven options by augmented intelligence might help enhance transplant affected person outcomes.”
“Transplant sufferers are on the pinnacle of healthcare. What we’re discussing on the International Kidney Improvements summit is the vanguard of care. We proceed to innovate and push the creativeness of what’s potential at CareDx,” stated Peter Maag, Chairman and CEO of CareDx.
To register for the Second Annual International Summit: International Kidney Improvements – Increasing Affected person Decisions & Outcomes, hosted by the American Affiliation of Kidney Sufferers and George Washington College, please go to: https://bit.ly/3gFCOTr
CareDx, Inc., headquartered in South San Francisco, California, is a number one precision drugs options firm targeted on the invention, improvement and commercialization of clinically differentiated, high-value healthcare options for transplant sufferers and caregivers. CareDx provides testing companies, merchandise, and digital healthcare options alongside the pre- and post-transplant affected person journey, and is the main supplier of genomics-based data for transplant sufferers. For extra data, please go to: www.CareDx.com.
Chief Advertising and marketing Officer
— to www.biospace.com